文献速递泌尿男性生殖肿瘤

PRESTO:在高危生化复发去势敏感前列腺癌患者中强化雄激素阻断的III期开放标签研究(AFT-19)

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
PubMed 文献 · J Clin Oncol · 2024-01-23

PRESTO是一项随机III期开放标签试验,纳入503例根治性前列腺切除术后生化复发且PSA倍增时间≤9个月的患者,1:1:1随机接受52周ADT、ADT+阿帕他胺或ADT+阿帕他胺+醋酸阿比特龙+泼尼松治疗。首次计划中期分析显示,两个实验组均较ADT对照组显著延长PSA-PFS,中位PSA-PFS分别为24.9个月和26.0个月 vs 20.3个月(ADT+阿帕他胺+AAP组为26.0个月 vs 20.0个月),最常见≥3级不良事件为高血压。结论认为有限疗程强化AR阻断可延长PSA-PFS且安全性可控,不影响睾酮恢复时间,高危BRPC患者应考虑在ADT基础上加用阿帕他胺。

要点

  • ADT+阿帕他胺组中位PSA-PFS 24.9个月 vs ADT组20.3个月,HR 0.52(95%CI 0.35-0.77),P=.00047。
  • ADT+阿帕他胺+AAP组中位PSA-PFS 26.0个月 vs ADT组20.0个月,HR 0.48(95%CI 0.32-0.71),P=.00008。
  • ≥3级高血压发生率:ADT组7.5%、ADT+阿帕他胺组7.4%、ADT+阿帕他胺+AAP组18%。

核心结论

  • 有限疗程强化AR阻断可延长高危生化复发去势敏感前列腺癌患者的PSA-PFS,安全性可控,且不影响睾酮恢复时间。
  • 作者认为高危BRPC患者应考虑在ADT基础上加用阿帕他胺。

研究设计与样本

  • PRESTO为随机III期开放标签试验(ClinicalTrials.gov NCT03009981),纳入根治性前列腺切除术后生化复发且PSA倍增时间≤9个月的患者。
  • 503例患者按1:1:1随机分配接受52周ADT、ADT+阿帕他胺或ADT+阿帕他胺+醋酸阿比特龙+泼尼松(AAP)治疗。
  • 主要终点为PSA无进展生存(PSA-PFS),定义为治疗结束后血清PSA>0.2 ng/mL。

主要发现

  • 首次计划中期分析时,ADT+阿帕他胺组中位PSA-PFS为24.9个月 vs ADT组20.3个月,HR 0.52(95%CI 0.35-0.77),P=.00047。
  • ADT+阿帕他胺+AAP组中位PSA-PFS为26.0个月 vs ADT组20.0个月,HR 0.48(95%CI 0.32-0.71),P=.00008。
  • 中位睾酮恢复时间在各治疗组间无差异。
  • 最常见的≥3级不良事件为高血压,发生率在ADT组为7.5%、ADT+阿帕他胺组为7.4%、ADT+阿帕他胺+AAP组为18%。

关键数值与推荐

  • 入组条件:根治性前列腺切除术后生化复发,PSA倍增时间≤9个月。
  • 治疗方案:ADT对照、ADT+阿帕他胺或ADT+阿帕他胺+AAP,疗程为52周。
  • 主要终点PSA-PFS定义:治疗结束后血清PSA>0.2 ng/mL。

临床怎么用

  • 作者结论指出,高危生化复发去势敏感前列腺癌患者应考虑在ADT基础上加用阿帕他胺。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong survival in the metastatic setting. We evaluated whether intensification of androgen-deprivation therapy (ADT) improves outcomes in BRPC. PATIENTS AND METHODS: PRESTO is a randomized phase III, open-label trial in patients with BRPC and PSA doubling time ≤9 months (ClinicalTrials.gov identifier: NCT03009981). Patients were randomly assigned 1:1:1 to receive a finite 52-week treatment course with ADT control, ADT + apalutamide, or ADT + apalutamide + AAP. The primary end point was PSA progression-free survival (PSA-PFS), defined as serum PSA >0.2 ng/mL after treatment completion. RESULTS: Five hundred three patients were enrolled. The median PSA was 1.8 ng/mL (IQR, 1.0-3.6). At the first planned interim analysis, both experimental arms significantly prolonged PSA-PFS compared with the control arm (median, 24.9 months for ADT + apalutamide v 20.3 months for ADT; hazard ratio [HR], 0.52 [95% CI, 0.35 to 0.77]; P = .00047; median, 26.0 months for ADT + apalutamide + AAP v 20.0 months for ADT; HR, 0.48 [95% CI, 0.32 to 0.71]; P = .00008). Median time to testosterone recovery did not differ across treatment arms. The most common grade ≥3 adverse event was hypertension (7.5%, 7.4%, and 18% in ADT, ADT + apalutamide, and ADT + apalutamide + AAP arms, respectively). CONCLUSION: Intensified AR blockade for a finite duration prolongs PSA-PFS with a manageable safety profile, without adversely affecting time to testosterone recovery. The addition of apalutamide to ADT should be considered in patients with high-risk BRPC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Heller G, Hillman DW, et al. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024. PMID: 38261983. doi:10.1200/JCO.23.01157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。